Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Cryptococcal meningoencephalitis (CM) can cause significant morbidity and mortality in previously healthy, non-HIV-infected patients, with all-cause mortality as high as 29% at 1 year.1 Clinical deterioration following microbiological control often results from a postinfectious inflammatory response syndrome (PIIRS). This syndrome may often result in intracranial hypertension (IH) and/or hydrocephalus (HCP).2 Ventricular shunting can provide sustained relief from IH/HCP and improve neurological outcomes.3 However, persistent neurological sequelae, which occur in a subset of patients, may lead to shunt revisions and poor long-term outcomes.3 Corticosteroids have been proposed to improve outcomes in selected, relatively immunocompetent patients with CM, but are often avoided due to presumed immunosuppressive effects.4 5 Paradoxically, the use of corticosteroids during initial therapy of other patient populations such as HIV-associated CM has been found to result in worse overall outcomes.4 We hypothesised that corticosteroid salvage therapy (CST) may have specific utility in previously healthy patients with PIIRS following microbiological control with persistent neurological sequelae and report our experience in a cohort of patients who have already undergone cerebrospinal fluid (CSF) diversion.
Previously healthy patients who were evaluated and treated for cryptococcal meningitis between 2011 and 2016 at the National Institutes of Health (NIH) were identified. Informed consent to participate in clinical research was obtained from all patients (NIH protocol 93-I-0106). We limited assessment to a relatively uniform population of patients who had previously undergone CSF …
Contributors All authors contributed to this manuscript and meet the criteria for authorship.
Funding This research was supported by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Competing interests PRW has a cooperative research and development agreement with Matinas BioPharma regarding an oral amphotericin formulation.
Patient consent Obtained.
Ethics approval NIH Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.